Krystal Biotech Inc
For the period ended Sep 30, 2024. Filed Nov 4, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 4, 2024
KRYS$306.50+1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows for the and
Condensed Consolidated Statements of Cash Flows
| Nine Months Ended September 30, | ||
|---|---|---|
| (in thousands) | 2024 | 2023 |
| Operating Activities | ||
| Net income | $43,680 | $2,240 |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities | ||
| Gain from sale of priority review voucher | — | (100,000) |
| Depreciation | 4,603 | 3,483 |
| Accretion on marketable securities | (1,535) | (1,585) |
| Amortization of operating lease right-of-use assets | 556 | 671 |
| Stock-based compensation expense, net | 35,771 | 30,080 |
| Realized gain on investments | (4,427) | (3,886) |
| Other, net | 725 | (77) |
| Changes in operating assets and liabilities | ||
| Accounts receivable, net | (55,257) | (9,316) |
| Inventory | (5,386) | (3,983) |
| Prepaid expenses and other current assets | (2,636) | (464) |
| Other non-current assets | 11 | (48) |
| Lease liability | (617) | (603) |
| Other long-term liabilities | 761 | — |
| Accounts payable | 1,602 | 121 |
| Accrued expenses and other current liabilities | (2,092) | 875 |
| Accrued rebates | 23,568 | 920 |
| Accrued litigation settlement | 31,250 | — |
| Net cash provided by (used in) operating activities | 70,577 | (81,572) |
| Investing Activities | ||
| Proceeds from sale of priority review voucher | — | 100,000 |
| Purchases of property and equipment | (3,437) | (9,952) |
| Purchases of investments | (314,268) | (425,870) |
| Maturities of investments | 238,044 | 428,620 |
| Net cash (used in) provided by investing activities | (79,661) | 92,798 |
| Financing Activities | ||
| Proceeds from issuance of common stock, net of offering costs | — | 159,716 |
| Proceeds from exercise of stock options | 29,972 | 41,164 |
| Taxes paid for employee tax withholding related to restricted stock units | (4,181) | — |
| Taxes paid related to settlement of restricted stock awards | (1,205) | (749) |
| Net cash provided by financing activities | 24,586 | 200,131 |
| Effect of exchange rate changes on cash and cash equivalents | 136 | (16) |
| Net increase in cash and cash equivalents | 15,638 | 211,341 |
| Cash and cash equivalents at beginning of period | 358,328 | 161,900 |
| Cash and cash equivalents at end of period | $373,966 | $373,241 |
| Supplemental Disclosures of Non-Cash Investing Activities | ||
| Unpaid purchases of property and equipment included in accounts payable and accrued expenses | $8,292 | $11,103 |
| Supplemental Cash Flow Information | ||
| Income taxes paid | $5,150 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.